J Korean Med Sci.  2014 May;29(5):729-734. 10.3346/jkms.2014.29.5.729.

Serum Leptin and Adiponectin Levels in Korean Patients with Psoriasis

• Oh YJ
• Lim HK
• Choi JH
• Lee JW
• Kim NI

• KMID: 1786117
• DOI: http://doi.org/10.3346/jkms.2014.29.5.729

Abstract

Psoriasis is a disorder caused by genetic and immunological factors. Leptin, a peptide hormone secreted predominantly from adipose tissue, regulates energy intake and expenditure, as well as the T-helper response. There have been conflicting reports regarding serum levels of leptin and adiponectin in patients with psoriasis. In the present study, we measured serum levels of leptin and adiponectin in Korean patients with psoriasis. Twenty-four patients with psoriasis and fifteen control subjects were included in the study. Serum leptin and adiponectin levels were determined by an immunometric sandwich enzyme-linked immunosorbent assay (ELISA). The mean serum leptin concentration in patients with psoriasis was higher than in controls, and the difference was statistically significant. In contrast, serum adiponectin levels in patients with psoriasis were significantly decreased compared with healthy controls. Leptin levels in vitamin D-deficient patients were statistically significantly higher than in vitamin D-sufficient patients. Serum adiponectin concentrations showed a negative correlation with body mass index (BMI) and psoriasis area and severity index (PASI) in patients with psoriasis. In conclusion, the present study demonstrated that leptin and adiponectin may play a role in the immunopathogenesis of psoriasis and may be useful biomarkers indicating severity of psoriasis in Korean patients.

Keyword

Adiponectin; Leptin; Metabolic Syndrome; Psoriasis

MeSH Terms

Adiponectin/*blood
Adult
Aged
Biological Markers/blood
Body Mass Index
Enzyme-Linked Immunosorbent Assay
Female
Humans
Inflammation/immunology
Leptin/*blood
Male
Middle Aged
Psoriasis/*blood/*epidemiology
Republic of Korea/epidemiology
Risk
Severity of Illness Index
Vitamin D/blood
Vitamin D Deficiency/*blood
Young Adult
Adiponectin
Biological Markers
Leptin
Vitamin D

Figure

• 

  Fig. 1 Serum adiponectin (A) and leptin (B) levels in patients and controls. Values noted are medians.

• 

  Fig. 2 Correlation between serum leptin levels and age (A), BMI (B), and PASI (C).

• 

  Fig. 3 Correlation between serum adiponectin levels and age (A), BMI (B), PASI (C).

Reference

1. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol. 2006; 54:S67–S80.

2. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, Bruni PL, Ingordo V, Lo Scocco G, Solaroli C, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005; 125:61–67.

3. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gómez-Reino JJ, Gualillo O. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 2005; 579:295–301.

4. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens). 2012; 11:8–20.

5. Hulthe J, Hultén LM, Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism. 2003; 52:1612–1614.

6. Saeki H, Shibata S, Tada Y, Karakawa M, Minatani Y, Tamaki K. Psoriasis arthropathica associated with severe obesity showing high serum leptin level. J Dermatol. 2009; 36:364–366.

7. Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI, Steinsson JT, Elder JT, Valdimarsson H. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol. 2008; 159:342–350.

8. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, Krueger GG. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005; 141:1527–1534.

9. Choi WJ, Park EJ, Kwon IH, Kim KH, Kim KJ. Association between psoriasis and cardiovascular risk factors in Korean patients. Ann Dermatol. 2010; 22:300–306.

10. Kim GW, Park HJ, Kim HS, Kim SH, Ko HC, Kim BS, Kim MB, Sim EK. Analysis of cardiovascular risk factors and metabolic syndrome in korean patients with psoriasis. Ann Dermatol. 2012; 24:11–15.

11. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006; 55:829–835.

12. Bonifati C, Carducci M, Cordiali Fei P, Trento E, Sacerdoti G, Fazio M, Ameglio F. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients: relationships with disease severity. Clin Exp Dermatol. 1994; 19:383–387.

13. Sterry W, Strober BE, Menter A. International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications: report of an interdisciplinary conference and review. Br J Dermatol. 2007; 157:649–655.

14. Khabour OF, Wehaibi SH, Al-Azzam SI, Alzoubi KH, El-Akawi ZJ. Association of adiponectin with hypertension in type 2 diabetic patients: the gender effect. Clin Exp Hypertens. 2013; 35:361–366.

15. Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, Chen CM. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008; 144:1571–1575.

16. Conde J, Gomez R, Bianco G, Scotece M, Lear P, Dieguez C, Gomez-Reino J, Lago F, Gualillo O. Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. Ann Rheum Dis. 2011; 70:551–559.

17. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbasi MO, Ergun T. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol. 2008; 159:820–826.

18. Tartaglia LA. The leptin receptor. J Biol Chem. 1997; 272:6093–6096.

19. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002; 46:1–23.

20. Tanaka S, Inoue S, Isoda F, Waseda M, Ishihara M, Yamakawa T, Sugiyama A, Takamura Y, Okuda K. Impaired immunity in obesity: suppressed but reversible lymphocyte responsiveness. Int J Obes Relat Metab Disord. 1993; 17:631–636.

21. Huang L, Li C. Leptin: a multifunctional hormone. Cell Res. 2000; 10:81–92.

22. Dai Y, Pang J, Gong H, Fan W, Zhang TM. Roles and tissue source of adiponectin involved in lifestyle modifications. J Gerontol A Biol Sci Med Sci. 2013; 68:117–128.

23. Lee S, Zhang H, Chen J, Dellsperger KC, Hill MA, Zhang C. Adiponectin abates diabetes-induced endothelial dysfunction by suppressing oxidative stress, adhesion molecules, and inflammation in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2012; 303:H106–H115.

24. Li L, Wu LL. Adiponectin and interleukin-6 in inflammation-associated disease. Vitam Horm. 2012; 90:375–395.

25. Nakajima H, Nakajima K, Tarutani M, Sano S. Clear association between serum levels of adipokines and T-helper 17-related cytokines in patients with psoriasis. Clin Exp Dermatol. 2013; 38:66–70.

26. Russolillo A, Iervolino S, Peluso R, Lupoli R, Di Minno A, Pappone N, Di Minno MN. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford). 2013; 52:62–67.

27. Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U. Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis? Exp Dermatol. 2012; 21:43–47.

28. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol. 2008; 159:1207–1208.

29. Matarese G, Sanna V, Di Giacomo A, Lord GM, Howard JK, Bloom SR, Lechler RI, Fontana S, Zappacosta S. Leptin potentiates experimental autoimmune encephalomyelitis in SJL female mice and confers susceptibility to males. Eur J Immunol. 2001; 31:1324–1332.

30. Wang Y, Chen J, Zhao Y, Geng L, Song F, Chen HD. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol. 2008; 158:1134–1135.

31. Al-Daghri NM, Al-Attas OS, Alokail MS, Alkharfy KM, Al-Othman A, Draz HM, Yakout SM, Al-Saleh Y, Al-Yousef M, Sabico S, et al. Hypovitaminosis D associations with adverse metabolic parameters are accentuated in patients with Type 2 diabetes mellitus: a body mass index-independent role of adiponectin? J Endocrinol Invest. 2013; 36:1–6.

32. Enany B, El Zohiery AK, Elhilaly R, Badr T. Carotid intima-media thickness and serum leptin in psoriasis. Herz. 2012; 37:527–533.

33. Abdel Hay RM, Rashed LA. Association between the leptin gene 2548G/A polymorphism, the plasma leptin and the metabolic syndrome with psoriasis. Exp Dermatol. 2011; 20:715–719.

34. Kaur S, Zilmer K, Leping V, Zilmer M. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. J Eur Acad Dermatol Venereol. 2011; 25:1328–1333.

35. Aktan S, Rota S, Erdogan B, Ergin S, Kaptanoglu B, Bostanci M. A role of leptin in psoriasis? Turk J Med Sci. 2007; 37:135–138.